The Influence of Oral Contraceptives on the Risk of Multiple Sclerosis
Overview
Authors
Affiliations
Objective: To examine the risk of multiple sclerosis in users of combined oral contraceptives.
Design: Cohort study conducted between 1968 and 1996 using diagnostic data supplied by general practitioners
Setting: General practices throughout the United Kingdom.
Population: Royal College of General Practitioners' Oral Contraception Study cohort of initially 46,000 women recruited during the late 1960s.
Methods: Directly standardised incidence rates of multiple sclerosis were calculated for current, former and never-users of oral contraceptives using first ever cases of multiple sclerosis reported by the general practitioners. The standardisation variables were age, parity, social class and smoking history. Five-year survival rates in the different contraceptive groups were calculated using standard life table techniques.
Results: One hundred and fourteen first ever cases of multiple sclerosis had been reported by November 1996 during 564,000 woman-years of observation. The incidence rate in both current and former users was not materially different to that in never-users. Although based on limited evidence there was no suggestion that the five-year survival was affected by a woman's use of combined oral contraceptives.
Conclusions: These findings do not suggest a greatly elevated risk of multiple sclerosis during, or after, use of combined oral contraceptives.
Zhang Q, Noyce A, Robson J, Giovannoni G, Marshall C, Dobson R Mult Scler. 2024; 30(9):1221-1226.
PMID: 38877717 PMC: 11660507. DOI: 10.1177/13524585241258691.
Hatami A, Ahmadi-Khorram M, Keykhaei F, Esfehani A, Nematy M Clin Nutr Res. 2024; 13(1):61-73.
PMID: 38362132 PMC: 10866681. DOI: 10.7762/cnr.2024.13.1.61.
Ghajarzadeh M, Mohammadi A, Shahraki Z, Sahraian M, Mohammadifar M Int J Prev Med. 2022; 13:89.
PMID: 35958357 PMC: 9362753. DOI: 10.4103/ijpvm.IJPVM_299_20.
Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy.
Villaverde-Gonzalez R Degener Neurol Neuromuscul Dis. 2022; 12:1-21.
PMID: 35023987 PMC: 8743861. DOI: 10.2147/DNND.S203406.
Mitchell R, Bates K, Wootton R, Harroud A, Richards J, Davey Smith G PLoS Biol. 2020; 18(11):e3000973.
PMID: 33253141 PMC: 7728259. DOI: 10.1371/journal.pbio.3000973.